Biopharmaceutical company Navitor Pharmaceuticals has raised a $23.5m Series A round from venture capital backers.
Polaris Partners, Atlas Venture, Johnson & Johnson Development Corporation, SR One and The Longevity Fund participated in the round, which will support the development of a pipeline of drugs targeting cellular nutrient signaling via the mTORC1 pathway.
This will address metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders.
Navitor said it will develop its proprietary technologies, tools and assays to address the complexity of the mTORC1 pathway.
Polaris partner Alan Crane said, “Navitor represents a rare convergence of innovative science, world-class scientific advisors, and an experienced team with the potential to create significant value based on breakthrough science.
“We are excited to be a part of building a biopharmaceutical company with the potential to offer new approaches to treat a wide range of important diseases and have a significant impact for patients.”
Earlier this month AltAssets revealed that Polaris made a return of more than four times from the sale of security and infrastructure business AddPro private equity firm Perusa.
AddPro was sold after a holding period of nine years.
Copyright © 2014 AltAssets